Diffuse large B-cell lymphoma (DLBCL) is the commonest form of lymphoid malignancy, with a prevalence of about 40% worldwide. Its classification encompasses a common form, also termed as “not otherwise specified” (NOS), and a series of variants, which are rare and at least in part related to viral agents. Over the last two decades, DLBCL-NOS, which accounts for more than 80% of the neoplasms included in the DLBCL chapter, has been the object of an increasing number of molecular studies which have led to the identification of prognostic/predictive factors that are increasingly entering daily practice. In this review, the main achievements obtained by gene expression profiling (with respect to both neoplastic cells and the microenvironment) and next-generation sequencing will be discussed and compared. Only the amalgamation of molecular attributes will lead to the achievement of the long-term goal of using tailored therapies and possibly chemotherapy-free protocols capable of curing most (if not all) patients with minimal or no toxic effects.

Predictive and prognostic molecular factors in diffuse large b-cell lymphomas / S.A. Pileri, C. Tripodo, F. Melle, G. Motta, V. Tabanelli, S. Fiori, M.C. Vegliante, S. Mazzara, S. Ciavarella, E. Derenzini. - In: CELLS. - ISSN 2073-4409. - 10:3(2021), pp. 675.1-675.15. [10.3390/cells10030675]

Predictive and prognostic molecular factors in diffuse large b-cell lymphomas

S. Mazzara;E. Derenzini
2021

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the commonest form of lymphoid malignancy, with a prevalence of about 40% worldwide. Its classification encompasses a common form, also termed as “not otherwise specified” (NOS), and a series of variants, which are rare and at least in part related to viral agents. Over the last two decades, DLBCL-NOS, which accounts for more than 80% of the neoplasms included in the DLBCL chapter, has been the object of an increasing number of molecular studies which have led to the identification of prognostic/predictive factors that are increasingly entering daily practice. In this review, the main achievements obtained by gene expression profiling (with respect to both neoplastic cells and the microenvironment) and next-generation sequencing will be discussed and compared. Only the amalgamation of molecular attributes will lead to the achievement of the long-term goal of using tailored therapies and possibly chemotherapy-free protocols capable of curing most (if not all) patients with minimal or no toxic effects.
Classification; Diagnosis; Diffuse large B-cell lymphoma; Gene expression profiling; Next-generation sequencing; Prognosis; Therapy; Humans; Lymphoma, Large B-Cell, Diffuse; Microarray Analysis; Prognosis; Tumor Microenvironment; Gene Expression Profiling; High-Throughput Nucleotide Sequencing
Settore MED/15 - Malattie del Sangue
Article (author)
File in questo prodotto:
File Dimensione Formato  
cells-10-00675.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 3.94 MB
Formato Adobe PDF
3.94 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/877540
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact